{"nctId":"NCT00306384","briefTitle":"Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus","startDateStruct":{"date":"2006-03"},"conditions":["Diabetes Mellitus"],"count":3323,"armGroups":[{"label":"Alogliptin 12.5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Alogliptin"]},{"label":"Alogliptin 25 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Alogliptin"]}],"interventions":[{"name":"Alogliptin","otherNames":["SYR110322","SYR-322"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.\n* Type 2 diabetes mellitus and was enrolled in one of the following 7 controlled Phase III studies. The study will be open to all patients who completed one of these studies through the end-of-treatment visit:\n\n  * SYR-322-PLC-010 - NCT00286455\n  * SYR-322-SULF-007 - NCT00286468\n  * SYR-322-MET-008 - NCT00286442\n  * SYR-322-TZD-009 - NCT00286494\n  * SYR-322-INS-011 - NCT00286429\n  * 01-05-TL-322OPI-001 - NCT00328627\n  * 01-06-TL-322OPI-002 - NCT00395512\n* Alanine aminotransferase less than or equal to 3 times the upper limit of normal and serum creatinine less than or equal to 2.0 mg per dL.\n* Able and willing to monitor own blood glucose concentrations with a home glucose monitor.\n* No major illness or debility that in the investigator's opinion prohibits the patient from completing the study.\n\nExclusion Criteria\n\n* The occurrence of any adverse event or condition during the controlled Phase III studies, which, in the opinion of the investigator, should exclude the patient from participating in the open-label extension.\n* Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:\n\n  * Weight-loss drugs\n  * Investigational antidiabetics, additional dipeptidyl peptidase-4 (DPP-4) and glucagon-like peptide-1 (GLP 1) inhibitors\n  * Incretin Mimetics,\n  * Oral or systemically injected glucocorticoids.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)","description":"Safety was assessed by physical examinations, clinical laboratory parameters, electrocardiogram (ECG) readings, vital sign measurements, oral temperature, and hypoglycemic events. Changes in laboratory values or ECG parameters were considered to be adverse events if they were judged to be clinically significant. A TEAE was any event that started on or after the first dose of open-label study drug and within 14 days after the last dose.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.2","spread":null},{"groupId":"OG001","value":"87.1","spread":null},{"groupId":"OG002","value":"84.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.6","spread":null},{"groupId":"OG001","value":"22.7","spread":null},{"groupId":"OG002","value":"24.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":null},{"groupId":"OG001","value":"6.1","spread":null},{"groupId":"OG002","value":"7.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"16.3","spread":null},{"groupId":"OG002","value":"15.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":null},{"groupId":"OG001","value":"2.1","spread":null},{"groupId":"OG002","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"1.0","spread":null},{"groupId":"OG002","value":"0.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Over Time in Glycosylated Hemoglobin","description":"The change from Baseline in glycosylated hemoglobin (HbA1c; the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) during the study. Endpoint was defined as the last postbaseline observation collected within 7 days after the last dose of open-label study drug.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.21","spread":"0.815"},{"groupId":"OG001","value":"7.22","spread":"0.814"},{"groupId":"OG002","value":"9.30","spread":"0.900"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":"0.635"},{"groupId":"OG001","value":"0.14","spread":"0.632"},{"groupId":"OG002","value":"-0.52","spread":"1.064"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":"0.859"},{"groupId":"OG001","value":"0.26","spread":"0.848"},{"groupId":"OG002","value":"-0.73","spread":"1.285"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.34","spread":"0.969"},{"groupId":"OG001","value":"0.33","spread":"0.894"},{"groupId":"OG002","value":"-0.78","spread":"1.282"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.41","spread":"1.010"},{"groupId":"OG001","value":"0.41","spread":"0.952"},{"groupId":"OG002","value":"-0.78","spread":"1.309"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.47","spread":"0.990"},{"groupId":"OG001","value":"0.48","spread":"1.068"},{"groupId":"OG002","value":"-0.75","spread":"1.332"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"1.082"},{"groupId":"OG001","value":"0.50","spread":"1.047"},{"groupId":"OG002","value":"-0.70","spread":"1.320"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.52","spread":"1.096"},{"groupId":"OG001","value":"0.51","spread":"1.070"},{"groupId":"OG002","value":"-0.75","spread":"1.389"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.53","spread":"1.111"},{"groupId":"OG001","value":"0.58","spread":"1.107"},{"groupId":"OG002","value":"-0.69","spread":"1.417"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.58","spread":"1.124"},{"groupId":"OG001","value":"0.58","spread":"1.159"},{"groupId":"OG002","value":"-0.71","spread":"1.349"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.57","spread":"1.127"},{"groupId":"OG001","value":"0.57","spread":"1.167"},{"groupId":"OG002","value":"-0.78","spread":"1.361"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.55","spread":"1.181"},{"groupId":"OG001","value":"0.57","spread":"1.196"},{"groupId":"OG002","value":"-0.73","spread":"1.418"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":"1.215"},{"groupId":"OG001","value":"0.55","spread":"1.141"},{"groupId":"OG002","value":"-0.80","spread":"1.411"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.56","spread":"1.223"},{"groupId":"OG001","value":"0.56","spread":"1.216"},{"groupId":"OG002","value":"-0.73","spread":"1.431"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.59","spread":"1.225"},{"groupId":"OG001","value":"0.54","spread":"1.221"},{"groupId":"OG002","value":"-0.78","spread":"1.492"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.61","spread":"1.250"},{"groupId":"OG001","value":"0.56","spread":"1.242"},{"groupId":"OG002","value":"-0.70","spread":"1.398"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.63","spread":"1.310"},{"groupId":"OG001","value":"0.61","spread":"1.261"},{"groupId":"OG002","value":"-0.42","spread":"1.448"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose","description":"The change from Baseline in fasting plasma glucose (FPG) at the last post-baseline observation, collected within 7 days after the last dose of open-label study drug.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"144.4","spread":"41.64"},{"groupId":"OG001","value":"142.6","spread":"39.41"},{"groupId":"OG002","value":"215.3","spread":"60.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.8","spread":"56.25"},{"groupId":"OG001","value":"14.9","spread":"53.46"},{"groupId":"OG002","value":"-26.4","spread":"84.51"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Marked Hyperglycemia","description":"Marked Hyperglycemia is defined as fasting plasma glucose greater than or equal to 200 mg/dL (â‰¥11.10 mmol/L).\n\nThe Month 42 to Month 45 interval includes all marked hyperglycemic episodes occurring on or after Day 1247 (a 203-day visit window).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":null},{"groupId":"OG001","value":"8.0","spread":null},{"groupId":"OG002","value":"55.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":null},{"groupId":"OG001","value":"10.2","spread":null},{"groupId":"OG002","value":"45.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":null},{"groupId":"OG001","value":"11.0","spread":null},{"groupId":"OG002","value":"46.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":null},{"groupId":"OG001","value":"10.8","spread":null},{"groupId":"OG002","value":"41.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.0","spread":null},{"groupId":"OG001","value":"11.6","spread":null},{"groupId":"OG002","value":"39.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":null},{"groupId":"OG001","value":"10.7","spread":null},{"groupId":"OG002","value":"36.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":null},{"groupId":"OG001","value":"12.9","spread":null},{"groupId":"OG002","value":"32.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1","spread":null},{"groupId":"OG001","value":"13.0","spread":null},{"groupId":"OG002","value":"29.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.7","spread":null},{"groupId":"OG001","value":"13.8","spread":null},{"groupId":"OG002","value":"27.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":null},{"groupId":"OG001","value":"11.6","spread":null},{"groupId":"OG002","value":"26.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":null},{"groupId":"OG001","value":"11.5","spread":null},{"groupId":"OG002","value":"26.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","spread":null},{"groupId":"OG001","value":"12.3","spread":null},{"groupId":"OG002","value":"24.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.6","spread":null},{"groupId":"OG001","value":"11.8","spread":null},{"groupId":"OG002","value":"24.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","spread":null},{"groupId":"OG001","value":"11.7","spread":null},{"groupId":"OG002","value":"19.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":null},{"groupId":"OG001","value":"12.3","spread":null},{"groupId":"OG002","value":"23.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":null},{"groupId":"OG001","value":"12.5","spread":null},{"groupId":"OG002","value":"21.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.7","spread":null},{"groupId":"OG001","value":"13.1","spread":null},{"groupId":"OG002","value":"19.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.5","spread":null},{"groupId":"OG001","value":"23.9","spread":null},{"groupId":"OG002","value":"39.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.7","spread":null},{"groupId":"OG001","value":"50.7","spread":null},{"groupId":"OG002","value":"87.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Proinsulin Level","description":"Proinsulin is a precursor to insulin, and was measured as an indicator of pancreatic function. The change from Baseline in fasting proinsulin to the last post-baseline observation, collected within 7 days after the last dose of open-label study drug.\n\nNote: A transcription error occurred in the reporting of 1 proinsulin value for a patient in the alogliptin 25 mg completed group, for whom a partial patient ID number was mistakenly entered as an end-of-treatment proinsulin level.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.1","spread":"25.99"},{"groupId":"OG001","value":"25.4","spread":"30.28"},{"groupId":"OG002","value":"40.2","spread":"36.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"27.09"},{"groupId":"OG001","value":"39.7","spread":"1243.37"},{"groupId":"OG002","value":"-3.3","spread":"31.45"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Insulin Level","description":"The change from Baseline in fasting insulin at the last post-baseline observation, collected within 7 days after the last dose of open-label study drug.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.19","spread":"9.898"},{"groupId":"OG001","value":"15.50","spread":"12.608"},{"groupId":"OG002","value":"18.64","spread":"15.845"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.45","spread":"42.706"},{"groupId":"OG001","value":"2.13","spread":"16.496"},{"groupId":"OG002","value":"5.62","spread":"23.197"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in C-peptide Level","description":"C-peptide is a byproduct created when the hormone insulin is produced and is measured by a blood test. Change from Baseline to the last post-baseline observation, collected within 7 days after the last dose of open-label study drug.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.406","spread":"1.5115"},{"groupId":"OG001","value":"3.323","spread":"1.5945"},{"groupId":"OG002","value":"3.572","spread":"1.7531"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.471","spread":"1.6464"},{"groupId":"OG001","value":"-0.439","spread":"1.2783"},{"groupId":"OG002","value":"-0.641","spread":"1.5804"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight","description":"Change from Baseline in body weight to the last post-baseline observation collected within 7 days after the last dose of open-label study drug.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.12","spread":"19.376"},{"groupId":"OG001","value":"86.61","spread":"19.185"},{"groupId":"OG002","value":"88.62","spread":"20.947"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.64","spread":"5.283"},{"groupId":"OG001","value":"-0.61","spread":"5.428"},{"groupId":"OG002","value":"0.25","spread":"5.036"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Clinical Response","description":"Clinical response was defined based on the absolute value of HbA1c meeting one of two clinical targets at any post-baseline visit:\n\n* HbA1c â‰¤6.5%;\n* HbA1c â‰¤7.0%.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.8","spread":null},{"groupId":"OG001","value":"34.1","spread":null},{"groupId":"OG002","value":"11.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.1","spread":null},{"groupId":"OG001","value":"65.5","spread":null},{"groupId":"OG002","value":"27.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":233,"n":1394},"commonTop":["Hypertension","Urinary tract infection","Upper respiratory tract infection","Nasopharyngitis","Influenza"]}}}